echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > A picture to understand China PD-1/PD-L1 2021.12

    A picture to understand China PD-1/PD-L1 2021.12

    • Last Update: 2022-01-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    From the start of the first year of China's tumor immunity in June 2018 , it took a short period of 3 and a half years to December 12, 2021.

    Since the start of the first year of China's tumor immunization in June 2018 , it will take a short period of 3 and a half years to December 12, 2021.

    NMPA has approved 11 PD-1/PD-L1 products, involving 11 cancer types and 44 indications

    NMPA has approved 11 PD-1/PD-L1 products, involving 11 cancer types , 44 indications, 11 cancer types and 44 indications

    It is expected that many PD-1/PD-L1 products will be approved in 2022 , such as CStone, Fuhong, Jiahe, etc.

    Is expected in 2022 will have a variety of PD-1 / PD-L1 product is approved, the cornerstone for example, complex macros, and so on Kerry in 2022

    Non-small cell lung cancer : MSD, Hengrui, Baekje, Cinda have been approved as first-line squamous cell carcinoma and adenocarcinoma, and AZ is the only company in consolidation treatment
    .

    Non-small cell lung cancer : MSD, Hengrui, Baekje, Cinda have been approved as first-line squamous cell carcinoma and adenocarcinoma, and AZ is the only company in consolidation treatment
    .
    Non-small cell lung cancer Non-small cell lung cancer: MSD, Hengrui, Baiji, Cinda have been approved as first-line squamous cell carcinoma and adenocarcinoma, and AZ is the only company in consolidation treatment
    .

    Small cell lung cancer : AZ and Roche’s PD-L1 are the only first-line products
    .

    Small cell lung cancer : AZ and Roche’s PD-L1 are the only first-line products
    .
    Small cell lung cancer Small cell lung cancer: AZ and Roche's PD-L1 are the only first-line products
    .

    Liver cancer : Roche and Cinda are both approved first-line treatment for advanced stage
    .

    Liver cancer : Roche and Cinda are both approved first-line treatment for advanced stage
    .
    Liver cancer Liver cancer: Roche and Cinda have been approved first-line treatment for advanced stage
    .

    Esophageal cancer : MSD and Hengrui were approved first-line treatment for advanced stage
    .

    Esophageal cancer : MSD and Hengrui were approved first-line treatment for advanced stage
    .
    Esophageal cancer Esophageal cancer: MSD and Hengrui were approved first-line treatment for advanced stage
    .

    Gastric cancer : O drug is currently the only advanced first-line treatment
    .

    Gastric cancer : O drug is currently the only advanced first-line treatment
    .
    Gastric cancer: O drug is currently the only first-line treatment for advanced stage
    .

    Nasopharyngeal cancer : Hengrui and Junshi lead the first-line treatment
    .

    Nasopharyngeal cancer : Hengrui and Junshi lead the first-line treatment
    .
    Nasopharyngeal carcinoma: Hengrui and Junshi lead the first-line treatment
    .

    Head and neck cancer : MSD and BMS are both in the first line
    .

    Head and neck cancer : MSD and BMS are both in the first line
    .
    Head and neck cancer Head and neck cancer: MSD and BMS are both in the first line
    .

    Colorectal cancer : MSD is currently the only first-line treatment for MSI-H
    .

    Colorectal cancer : MSD is currently the only first-line treatment for MSI-H
    .
    Colorectal cancer Colorectal cancer: MSD is currently the only first-line treatment for MSI-H
    .

    Urothelial cancer : Junshi and Baekje lead, but both are second-line therapies
    .

    Urothelial cancer : Junshi and Baekje lead, but both are second-line therapies
    .
    Urothelial cancer Urothelial cancer: Junshi and Baekje lead, but both are second-line therapies
    .

    Melanoma : K drug and Junshi are leading, both are second-line treatments
    .

    Melanoma : K drug and Junshi are leading, both are second-line treatments
    .
    Melanoma

    Hodgkin's lymphoma : the densest, up to 5 types
    .

    Hodgkin's lymphoma : the densest, up to 5 types
    .
    Hodgkin's lymphoma Hodgkin's lymphoma: the most dense, as many as 5 types
    .



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.